The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: One size does not fit all

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 8, 2010, Pages 655-659

  Melmed, Gil Y ^a,c   Spiegel, Brennan M ^b,c   Bressler, Brian ^d   Cheifetz, Adam S ^e   Devlin, Shane M ^f   Harrell, Laura E ^g   Irving, Peter M ^h   Jones, Jennifer ⁱ   Kaplan, Gilaad G ^f   Kozuch, Patricia L ^j   Velayos, Fernando S ^k   Baidoo, Leonard ^l   Sparrow, Miles P ^m   Siegel, Corey A ^n,o  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Veteran's Administration   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF SASKATCHEWAN   (Canada)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF PITTSBURGH   (United States)

ⁿ ALFRED HOSPITAL   (Australia)

^o DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

more..

Author keywords

Adalimumab; Anti Tumor Necrosis Therapy; Certolizumab; Crohn's Disease; Inflammatory Bowel Disease; Infliximab

Indexed keywords

IMMUNOMODULATING AGENT; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGIC FACTOR; INFLIXIMAB; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; SMOKING; VALIDATION PROCESS; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; FEMALE; INFECTION; LYMPHOMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; INFECTION; LYMPHOMA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77955268121     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.04.023     Document Type: Article

References (20)

1. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
2. Baert F., Noman F., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
3. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
4. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
5. Ljung T., Karlén P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004, 53:849-853.
6. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
7. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
8. Rosh J.R., Gross T., Mamula P., et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?. Inflamm Bowel Dis 2007, 13:1024-1030.
9. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265-267.
10. Brook R.H., et al. The RAND/UCLA appropriateness method. Clinical practice guideline development: methodology perspectives 1994, Public Health Service, AHCR, Rockville, MD.
11. Feagan B.G., McDonald J., Ponich T., et al. A randomized trial of methotrexate in combination with infliximab for treatment of Crohn's disease. Gastroenterology 2008, 135:294.
12. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
13. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
14. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005, 129:807-818.
15. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
16. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
17. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
18. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
19. Vader J.-P., Froehlich F., Juillerat P., et al. Appropriate treatment for Crohn's disease: methodology and summary results of a multidisciplinary international expert panel approach-EPACT. Digestion 2006, 73:237-248.
20. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.